StockData
Annexon, Inc. logo

Annexon, Inc. (ANNX) stock

ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$3.52+0.05 (+1.44%)

Close on Nov 18, 2026Market cap $719.65MP/E –Yield 0.00%

Annexon operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Annexon's operating income for the twelve months ending Jun 30, 2026 was -$210.56M. For fiscal 2025 it was -$216.41M. The highest annual figure on record is -$32.52M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$216.41M–
FY2024Dec 31, 2024-$154.07M–
FY2023Dec 31, 2023-$143.72M–
FY2022Dec 31, 2022-$145.60M–
FY2021Dec 31, 2021-$130.71M–
FY2020Dec 31, 2020-$63.47M–
FY2019Dec 31, 2019-$32.52M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$57.23M–
Q1 FY2026Mar 31, 2026-$46.05M–
Q4 FY2025Dec 31, 2025-$50.26M–
Q3 FY2025Sep 30, 2025-$57.02M–
Q2 FY2025Jun 30, 2025-$51.73M–
Q1 FY2025Mar 31, 2025-$57.41M–
Q4 FY2024Dec 31, 2024-$52.48M–
Q3 FY2024Sep 30, 2024-$39.44M–
Q2 FY2024Jun 30, 2024-$33.58M–
Q1 FY2024Mar 31, 2024-$28.57M–
Q4 FY2023Dec 31, 2023-$30.01M–
Q3 FY2023Sep 30, 2023-$34.78M–
Q2 FY2023Jun 30, 2023-$37.69M–
Q1 FY2023Mar 31, 2023-$41.24M–
Q4 FY2022Dec 31, 2022-$36.70M–
Q3 FY2022Sep 30, 2022-$36.07M–
Q2 FY2022Jun 30, 2022-$37.41M–
Q1 FY2022Mar 31, 2022-$35.43M–
Q4 FY2021Dec 31, 2021-$37.46M–
Q3 FY2021Sep 30, 2021-$35.68M–
Q2 FY2021Jun 30, 2021-$31.37M–
Q1 FY2021Mar 31, 2021-$26.20M–
Q4 FY2020Dec 31, 2020-$23.19M–
Q3 FY2020Sep 30, 2020-$15.59M–
Q2 FY2020Jun 30, 2020-$12.24M–
Q1 FY2020Mar 31, 2020-$12.46M–
Q4 FY2019Dec 31, 2019-$9.13M–
Q3 FY2019Sep 30, 2019-$9.07M–
Q2 FY2019Jun 30, 2019-$8.22M–

More Annexon figures

See a number that looks wrong?